Veeva Systems (NYSE:VEEV) Stock Moved Up to “Buy” by Wall Street Zen

Wall Street Zen upgraded shares of Veeva Systems (NYSE:VEEV) from a hold rating to a buy rating in a report published on Saturday morning,Wall Street Zen reports.

A number of other brokerages also recently commented on VEEV. Oppenheimer lifted their price objective on shares of Veeva Systems from $225.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, August 17th. Mizuho upped their target price on shares of Veeva Systems from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $330.00 target price on shares of Veeva Systems in a report on Tuesday, September 8th. Royal Bank Of Canada raised their target price on shares of Veeva Systems from $275.00 to $325.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. Finally, Truist Financial lifted their price target on Veeva Systems from $262.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Nineteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Veeva Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $284.88.

Veeva Systems Stock Up 4.0%

Shares of Veeva Systems stock opened at $296.15 on Friday. The stock has a market cap of $47.95 billion, a P/E ratio of 48.71, a P/E/G ratio of 1.26 and a beta of 0.93. Veeva Systems has a 12-month low of $148.05 and a 12-month high of $302.17. The business’s 50 day moving average is $261.01 and its 200-day moving average is $203.58.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.12. The business had revenue of $927.96 million during the quarter, compared to analysts’ expectations of $905.38 million. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The firm’s revenue was up 17.6% on a year-over-year basis. During the same period last year, the business earned $1.99 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, sell-side analysts expect that Veeva Systems will post 6.70 EPS for the current year.

Insider Buying and Selling

In related news, EVP Daniel Rizzo sold 4,841 shares of the stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $276.51, for a total transaction of $1,338,584.91. Following the sale, the executive vice president owned 7,665 shares of the company’s stock, valued at $2,119,449.15. This represents a 38.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Priscilla Hung sold 750 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $261.04, for a total value of $195,780.00. Following the transaction, the director owned 3,242 shares in the company, valued at approximately $846,291.68. This trade represents a 18.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 51,591 shares of company stock valued at $13,355,945 over the last 90 days. 10.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in shares of Veeva Systems by 8.4% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 776 shares of the technology company’s stock valued at $173,000 after purchasing an additional 60 shares in the last quarter. Argos Wealth Advisors LLC raised its stake in Veeva Systems by 3.9% in the first quarter. Argos Wealth Advisors LLC now owns 1,720 shares of the technology company’s stock worth $302,000 after buying an additional 65 shares in the last quarter. Toth Financial Advisory Corp raised its stake in Veeva Systems by 24.1% in the third quarter. Toth Financial Advisory Corp now owns 335 shares of the technology company’s stock worth $96,000 after buying an additional 65 shares in the last quarter. Cim LLC lifted its holdings in Veeva Systems by 1.2% during the first quarter. Cim LLC now owns 5,778 shares of the technology company’s stock worth $1,015,000 after buying an additional 66 shares during the period. Finally, Concurrent Investment Advisors LLC lifted its holdings in Veeva Systems by 4.1% during the second quarter. Concurrent Investment Advisors LLC now owns 1,813 shares of the technology company’s stock worth $322,000 after buying an additional 71 shares during the period. Institutional investors own 88.20% of the company’s stock.

Key Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva’s strong second-quarter results, continued Vault CRM migrations and expansion of AI products support expectations for sustained growth. The company’s software remains deeply embedded in pharmaceutical and biotech workflows, creating customer retention and cross-selling opportunities. Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
• Positive Sentiment: Veeva highlighted new AI capabilities, including Veeva Falcon and Vault AI, along with enhancements to its Development Cloud and Quality Cloud applications. These tools could increase the value of its platform as drug developers seek faster research, clinical-trial and quality processes. Veeva Systems Showcases AI Innovations
• Positive Sentiment: Veeva Basics has reached nearly 200 customers and the company is drawing attention after reaching approximately 175 biotech customers, signaling adoption among emerging biopharma companies and a potentially broader long-term customer base. Veeva Basics Customer Update
• Positive Sentiment: Market commentary identifies Veeva as one of the software companies benefiting from institutional buying after earlier fears that AI could make subscription software obsolete. Its sticky customer data and strong switching costs are viewed as competitive advantages. Wall Street Left Software for Dead
• Neutral Sentiment: Evercore ISI raised its price target from $185 to $250, but that target is below the stock’s recent trading level, suggesting analysts may see less near-term upside after the rally. Evercore ISI Adjusts Veeva Price Target
• Negative Sentiment: Investors remain concerned that market saturation could limit growth, while valuation-focused analysis estimates the shares may be roughly 11% above fair value based on future cash generation. Veeva’s sharp advance also leaves the stock vulnerable to profit-taking if adoption or earnings momentum slows. Veeva Stock May Be Below Fair Value

About Veeva Systems

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.